PGG glucan - Biothera

Drug Profile

PGG glucan - Biothera

Alternative Names: B-glucan PGG; Complement receptor type 3 modulator - Biothera; CR3 modulator - Biothera; Imprime PGG; Soluble beta glucan - Biothera

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; Mayo Clinic; Merck
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Breast cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Pancreatic cancer
  • Preclinical Head and neck cancer; Myelosuppression
  • Research Follicular lymphoma
  • Suspended Infections
  • No development reported Stem cell mobilisation

Most Recent Events

  • 06 Dec 2016 Biothera and Merck plan a phase II trial for Head and neck cancer (Combination therapy, Second line therapy or greater) in Q2 2017(Biothera website, December 2016)
  • 05 Dec 2016 Biothera Pharmaceuticals and Merck expand their clinical collaboration to include Head and neck cancer (Combination therapy, Second line therapy or greater)
  • 01 Dec 2016 Phase-II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT02981303)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top